OpenAI kills Sora, pivots to enterprise
OpenAI shuttered its Sora video app and canceled a reported $1B Disney deal as it refocuses on enterprise AI, a move analysts call a sign of product prioritization. For healthcare vendors, that shift underscores buyer wariness about consumer-facing AI projects versus long-term, enterprise-grade support. (bbc.com)
OpenAI first previewed Sora in February 2024, released a public version in December 2024 and rolled out a standalone Sora 2 app in late September 2025 that topped app-store charts days after launch. (variety.com) Disney’s three-year licensing pact signed in December 2025 would have covered more than 200 Disney/Marvel/Pixar/Star Wars character licenses and included a planned $1 billion equity stake that never closed. (variety.com) Company communications and reporting show the cut followed a push to rein in high GPU and cloud costs, an applications all‑hands led by Fidji Simo, and moves to prioritize projects judged more durable ahead of a potential IPO at a roughly $730 billion valuation discussed internally and in markets. (cnbc.com) Product strategy documents and executive comments point to a consolidation toward enterprise-grade offerings—combining the ChatGPT app, web browser and Codex coding tools into a single productivity “super app”—as analysts contrasted that focus with rivals like Anthropic, which has pushed enterprise deployments. (cnbc.com) OpenAI told users it would publish timelines for the Sora app and API wind‑down and supply guidance on exporting or preserving projects created on the platform. (nbcnews.com) Gartner research cited by industry analysts shows a majority of U.S. healthcare consumers are hesitant to share personal data with GenAI tools, a statistic vendors point to when shifting procurement toward governed, auditable enterprise models. (gartner.com) Healthcare trade reporting highlights governance and accountability concerns for clinician‑facing AI (naming who is accountable for AI-influenced decisions) and documents a buyer trend toward outcome-based partnerships and operational SLAs rather than short-lived consumer pilots—context that frames why enterprise pivots may resonate with health systems. (healthcareitnews.com)
